Parkinsonism: A Simplified Overview
Parkinsonism is a clinical syndrome characterized by four cardinal motor signs: bradykinesia (slowness of movement), rigidity (muscle stiffness), tremor (typically at rest), and postural instability (balance problems). 1, 2, 1
What Causes Parkinsonism?
Parkinsonism has multiple causes that can be organized into distinct categories:
Neurodegenerative Causes (Dopamine Deficiency)
Idiopathic Parkinson's Disease (IPD): The most common cause, accounting for the majority of cases. This is a synucleinopathy where Lewy bodies (abnormal protein deposits containing alpha-synuclein) accumulate in brain neurons. Peak onset occurs between ages 60-70 years, with symptoms appearing after approximately 40-50% of dopaminergic neurons in the substantia nigra have been lost 2.
Atypical Parkinsonisms ("Parkinson-Plus" syndromes): These demonstrate classic parkinsonian features plus additional symptoms 2:
- Multiple System Atrophy (MSA): Includes prominent autonomic dysfunction (urinary incontinence, blood pressure problems), cerebellar symptoms (ataxia), or predominant parkinsonism. Onset typically 55-65 years 2.
- Progressive Supranuclear Palsy (PSP): Characterized by early falls, vertical gaze limitation (difficulty looking up/down), and axial rigidity. Mean onset age 63 years 2.
- Corticobasal Degeneration (CBD): Presents with asymmetric limb clumsiness, "alien limb phenomenon," and cortical features like apraxia. Onset 50-70 years 2.
- Dementia with Lewy Bodies (DLB): Parkinsonism with early prominent cognitive decline 1.
Non-Dopamine Deficiency Causes
- Drug-Induced Parkinsonism: Caused by dopamine-blocking medications (antipsychotics, antiemetics) 1
- Vascular Parkinsonism: Due to small vessel disease in the brain 1
- Essential Tremor: Tremor during voluntary movement (not at rest), though overlap can occur 1
- Psychogenic Parkinsonism: Functional/psychological origin 1
Key Clinical Signs to Identify
The diagnosis is clinical, based on identifying bradykinesia PLUS at least one of the following: rigidity, tremor, or postural instability 3, 4.
Motor Features
- Bradykinesia: Slowness initiating and executing movements, reduced amplitude of repetitive movements
- Rigidity: "Cogwheel" stiffness when limbs are moved passively
- Resting Tremor: Typically 4-6 Hz, present at rest, improves with movement (distinguishes from essential tremor)
- Postural Instability: Impaired balance, falls (usually later in disease)
- Asymmetric Onset: Symptoms typically start on one side 2
Non-Motor Features (often present and impact quality of life) 5, 2, 4
- Neuropsychiatric: Depression, anxiety, cognitive impairment, psychosis
- Autonomic: Constipation, urinary problems, orthostatic hypotension
- Sleep Disorders: REM sleep behavior disorder, insomnia
- Sensory: Loss of smell (hyposmia), pain
- Gastrointestinal: Dysphagia (swallowing difficulty), gastroparesis
Diagnostic Approach
Clinical diagnosis is paramount. Look for:
- Bradykinesia combined with rigidity and/or rest tremor
- Asymmetric symptom onset
- Good response to levodopa (supports Parkinson's disease diagnosis) 3, 4
Dopamine transporter (DAT) SPECT imaging can improve diagnostic accuracy when parkinsonism is uncertain, helping distinguish neurodegenerative causes (abnormal scan) from non-dopamine deficiency causes like essential tremor or drug-induced parkinsonism (normal scan) 1.
MRI of the brain is useful to exclude structural lesions, vascular disease, or identify patterns of atrophy characteristic of atypical parkinsonisms (MSA, PSP, CBD) 2.
Treatment Strategies
For Idiopathic Parkinson's Disease
Levodopa remains the gold standard and most effective treatment for motor symptoms 4, 6. It replaces depleted dopamine in the brain.
Treatment algorithm:
Initial therapy: Levodopa (with carbidopa) or dopamine agonists
Advanced disease with complications: Add adjuvant therapy
- COMT inhibitors (extend levodopa duration)
- MAO-B inhibitors
- Additional dopamine agonists 6
Medication-resistant tremor, severe "off" periods, or dyskinesias: Consider deep brain stimulation (subthalamic nucleus) or levodopa-carbidopa enteral suspension 4, 6
Non-Motor Symptom Management 4, 7
- Depression/Anxiety: SSRIs
- Cognitive decline: Cholinesterase inhibitors
- Psychosis: Reduce antiparkinsonian medications first; if needed, use quetiapine or clozapine (avoid typical antipsychotics)
- Constipation: Increased fluids, fiber, stool softeners
- Sleep disorders: Melatonin, clonazepam for REM sleep behavior disorder
Non-Pharmacologic Approaches
Exercise and physical therapy are essential components of management and should be prescribed alongside medications 5, 4, 8. Benefits include:
- Improved motor symptoms
- Reduced freezing of gait
- Better balance and reduced fall risk
- Enhanced quality of life
- Potentially slower disease progression
Additional therapies:
Atypical Parkinsonisms
These conditions are largely treatment-resistant to dopaminergic therapy 2. Management focuses on:
- Symptomatic treatment (limited levodopa response may occur in some MSA-P and PSP-P patients)
- Physical/occupational therapy
- Management of specific features (autonomic dysfunction in MSA, falls prevention in PSP)
- Palliative care planning given poorer prognosis
Critical Management Pitfalls
In Hospitalized Patients 9
- Medication timing errors: Even slight delays can cause severe "off" periods, falls, and aspiration risk. Administer PD medications on the patient's home schedule.
- Dopamine-blocking medications: Avoid metoclopramide, prochlorperazine, and typical antipsychotics—these worsen parkinsonism.
- Immobility: Enforce early mobilization; 28% of hospitalized patients show measurable motor decline.
- Dysphagia screening: Essential to prevent aspiration pneumonia (affects 36.9% of PD patients, with >65% one-year mortality post-aspiration) 9.
Nutritional Monitoring 5
- Regular weight monitoring (both loss and gain occur)
- Supplement vitamin D, folic acid, and B12 as needed
- Address dysphagia and constipation proactively
Bone Health 10
- High fracture risk due to falls, postural instability, and low bone mineral density
- Screen for osteoporosis and implement prevention strategies
No disease-modifying therapies currently exist—all treatments are symptomatic 4, 11. The focus remains on optimizing motor and non-motor symptom control, maintaining function, and maximizing quality of life through combined pharmacologic and rehabilitative approaches.